{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T18:29:46Z","timestamp":1762108186734,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012157","name":"Shanghai Key Discipline Construction Project","doi-asserted-by":"publisher","award":["GWVI-2.2","GWVI-11.2-YQ01","GWVI-11.1-15"],"award-info":[{"award-number":["GWVI-2.2","GWVI-11.2-YQ01","GWVI-11.1-15"]}],"id":[{"id":"10.13039\/501100012157","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015359","name":"Shanghai Medical College, Fudan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008750","name":"Shanghai Municipal Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC12022121"],"award-info":[{"award-number":["SHDC12022121"]}],"id":[{"id":"10.13039\/501100008750","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.cellimm.2025.104992","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T18:28:39Z","timestamp":1749925719000},"page":"104992","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy and safety of interferon alpha-2b aerosol therapy for patients infected with the SARS-CoV-2 omicron variant: A randomized controlled single-blind study"],"prefix":"10.1016","volume":"414","author":[{"given":"Yinpeng","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianming","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiping","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7871","key":"10.1016\/j.cellimm.2025.104992_bb0010","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization","volume":"596","author":"Planas","year":"2021","journal-title":"Nature"},{"year":"2025","series-title":"The Drug instructions of Recombinant Human Interferon \u03b12b Spray (Pseudomonas)","author":"Tianjin Weiming Biopharmaceutical Co., Ltd","key":"10.1016\/j.cellimm.2025.104992_bb0015"},{"issue":"3","key":"10.1016\/j.cellimm.2025.104992_bb0020","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nm1001","article-title":"Pegylated interferon-alpha protects type 1 pneumocytesagainst sars coronavirus infection in macaques","volume":"10","author":"Haagmans","year":"2004","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.cellimm.2025.104992_bb0025","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2111600119","article-title":"Differential interferon-\u03b1 subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection","volume":"119","author":"Schuhenn","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.cellimm.2025.104992_bb0030","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for covid-19 - interim who solidaritytrial results","volume":"384","author":"Pan","year":"2021","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1016\/j.cellimm.2025.104992_bb0035","first-page":"1967","article-title":"Peginterferon lambda-1a for treatment of outpatientswith uncomplicated covid-19: a randomized placebo-controlled trial","volume":"12","author":"Jagannathan","year":"2021","journal-title":"NatCommun"},{"issue":"12","key":"10.1016\/j.cellimm.2025.104992_bb0040","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S2213-2600(21)00384-2","article-title":"Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone inhospitalised adults with covid-19: A double-bind, randomised, placebo-controlled,phase 3 trial","volume":"9","author":"Kalil","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"10.1016\/j.cellimm.2025.104992_bb0045","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s12275-022-1525-1","article-title":"Sars-Cov-2-mediated evasion strategies for antiviralinterferon pathways","volume":"60","author":"Oh","year":"2022","journal-title":"J. Microbiol."},{"issue":"3","key":"10.1016\/j.cellimm.2025.104992_bb0050","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41422-022-00619-9","article-title":"Reduced interferon antagonism but similar drug sensitivity in omicron variant compared todelta variant of sars-Cov-2 isolates","volume":"32","author":"Bojkova","year":"2022","journal-title":"Cell Res."},{"key":"10.1016\/j.cellimm.2025.104992_bb0055","article-title":"Cinatl JJr.Sars-Cov-2 omicron variant virus isolates are highly sensitive to interferontreatment","volume":"8(1):42","author":"Bojkova","year":"2022","journal-title":"Cell Discovery"},{"issue":"28","key":"10.1016\/j.cellimm.2025.104992_bb0060","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1016\/j.vaccine.2010.03.062","article-title":"A randomizedcontrolled trial of low-dose recombinant human interferons alpha-2b spray toprevent acute viral respiratory infections in military recruits","volume":"28","author":"Gao","year":"2010","journal-title":"Vaccine"},{"author":"WHO","key":"10.1016\/j.cellimm.2025.104992_bb0065"},{"issue":"6","key":"10.1016\/j.cellimm.2025.104992_bb0070","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1473-3099(20)30232-2","article-title":"Viral dynamics in mild and severe cases of COVID-19","volume":"20","author":"Liu","year":"2020","journal-title":"Lancet Infect. Dis."},{"issue":"5","key":"10.1016\/j.cellimm.2025.104992_bb0075","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jinf.2020.03.004","article-title":"Clinical progression of patients with COVID-19 in Shanghai","volume":"80","author":"Chen","year":"2020","journal-title":"China. J Infect"},{"year":"2022","series-title":"The sars-Cov-2 variant, omicron, shows rapid replication in human primary nasalepithelial cultures and efficiently uses the endosomal route of entry. bioRxiv","author":"Peacock","key":"10.1016\/j.cellimm.2025.104992_bb0080"},{"issue":"7902","key":"10.1016\/j.cellimm.2025.104992_bb0085","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41586-022-04479-6","article-title":"SarsCov-2 omicron variant replication in human bronchus and lung ex vivo","volume":"603","author":"Hui","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.cellimm.2025.104992_bb0090","doi-asserted-by":"crossref","first-page":"1198576","DOI":"10.3389\/fmed.2023.1198576","article-title":"Interferons in COVID-19: missed opportunities to prove efficacy in clinical phase III trials?[J]","volume":"10","author":"Josef Brzoska","year":"2023","journal-title":"Front. Med."},{"issue":"1","key":"10.1016\/j.cellimm.2025.104992_bb0095","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41564-020-00835-2","article-title":"Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets","volume":"6","author":"Cox","year":"2021","journal-title":"Nat. Microbiol."},{"issue":"12","key":"10.1016\/j.cellimm.2025.104992_bb0100","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.3390\/v13122345","article-title":"Hydroxypropyl methylcellulose-based sprayseffectively inhibit in vitro sars-Cov-2 infection and spread","volume":"13","author":"Bentley","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.cellimm.2025.104992_bb0105","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ijid.2021.08.044","article-title":"Efficacy and safety of pegylated interferon-\u03b12b in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study","volume":"111","author":"Bhushan","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.cellimm.2025.104992_bb0110","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa2209760","article-title":"Early treatment with pegylated interferon lambda for COVID-19","volume":"388","author":"Reis","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellimm.2025.104992_bb0115","doi-asserted-by":"crossref","first-page":"e01410","DOI":"10.1128\/JVI.01410-20","article-title":"Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV","volume":"94","author":"Lokugamage","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.cellimm.2025.104992_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104811","article-title":"Antiviral activities of type I interferons to SARS-CoV-2 infection","volume":"179","author":"Mantlo","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.cellimm.2025.104992_bb0125","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","article-title":"Shared and distinct functions of type I and type III interferons","volume":"50","author":"Lazear","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.cellimm.2025.104992_bb0130","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.chom.2020.05.008","article-title":"Type I and type III interferons- induction, signaling, evasion, and application to combat COVID-19","volume":"27","author":"Park","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.cellimm.2025.104992_bb0135","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.648004","article-title":"Blood interferon-\u03b1 levels and severity, outcomes, and inflammatory profiles in hospitalized COVID-19 patients","volume":"12","author":"Contoli","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cellimm.2025.104992_bb0140","doi-asserted-by":"crossref","first-page":"7092","DOI":"10.1038\/s41467-021-27318-0","article-title":"Delayed induction of type I and iii interferons mediates nasal epithelial cellpermissiveness to sars-Cov-2","volume":"12","author":"Hatton","year":"2021","journal-title":"Nat. Commun."}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874925000784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874925000784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T18:24:51Z","timestamp":1762107891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008874925000784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":27,"alternative-id":["S0008874925000784"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2025.104992","relation":{},"ISSN":["0008-8749"],"issn-type":[{"type":"print","value":"0008-8749"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of interferon alpha-2b aerosol therapy for patients infected with the SARS-CoV-2 omicron variant: A randomized controlled single-blind study","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2025.104992","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104992"}}